top left corner image top right corner image

Using immunology to fight cancer

Scancell is developing novel immunotherapies for the treatment of cancer based upon its ImmunoBody® and Moditope® technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase II clinical trials.


Share price

AIM logoScancell Holdings plc is an AIM listed company.

View latest share price

Webcasts and interviews